Leerink Partners Maintains Outperform on Pharvaris, Raises Price Target to $65

Benzinga Newsdesk www.benzinga.com Positive 89.4%

Neg 0% Neu 0% Pos 89.4%

Leerink Partners analyst Joseph Schwartz maintains Pharvaris (NASDAQ:PHVS) with a Outperform and raises the price target from $50 to $65.